ROLE OF cMYBP-C IN THE DIAGNOSIS OF ACUTE CORONARY SYNDROME.

In patients with (ACS ), it is necessary to identify a sensitive biomarker for early diagnosis to avoid misdiagnosis of this serious condition and despite the high sensitivity and specificity of troponin in this context, the diagnosis of ACS represents a challenge. cMYBP-C might improve the ability of early diagnosis of ACS and the aim of the current study is to evaluate its role in the diagnosis depending on troponin as a reference biomarker. A total number of 150 patients with ACS were randomly selected to participate in the current study. They were equally divided into ST-elevation myocardial infarction (STTEMI), patients with non-ST elevation myocardial infarction (NSTEMI) and unstable angina (UA )in addition to50 individuals as a control healthy group. All participants were investigated for both troponin and c-MYBP-Cand the results were statistically evaluated. The current study has shown a significant increase in serum level of c-MYBP-C in patients with ACS apart from those with unstable angina when compared to the control group. This increase was so comparable to troponin increase that both biomarkers were even significantly higher in STEMI compared to NSTEMI. In those with unstable angina, there was no significant difference in both biomarkers compared to the control group. c-MYBP-Cis a useful biomarker for early diagnosis of ACS and in differentiating myocardial infarction (whether STEMI or NSTEMI) from unstable angina. [ABSTRACT FROM AUTHOR]